Dr. Mohammad Hirmand, M.D., joined Peloton Therapeutics in 2017 as Chief Medical Officer. Dr. Hirmand most recently served as Chief Medical Officer at Medivation (recently acquired by Pfizer), where he played a vital role in advancing XTANDI® (enzalutamide) through clinical trials that led to its approval by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. His responsibilities also included the in-licensing and global clinical development of the poly ADP ribose polymerase (PARP) inhibitor, talazoparib. Prior to Medivation, he was Senior Director of Clinical Development at Nuvelo, Inc. (now ARCA Biopharma), where he led the Clinical Operations, Clinical Data Management and Clinical Sciences/Medical Monitor staff. He has also served as Director of Oncology Development at SuperGen, Inc. (now Astex Pharmaceuticals, Inc.) and as Associate Director of Clinical Research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik’s oncology trials. Dr. Hirmand received his M.D. from Harvard Medical School and his B.A. in Biological Sciences and Economics from Cornell University.